Consolidated balance sheet

in CHF 1 000	Notes	30.06.2024	31.12.2023
Current assets
Cash and cash equivalents		317	501
Receivables from brokers		–	1 829
Securities	3	2 708 893	2 634 714
Other assets		214	110
		2 709 424	2 637 154
Total assets		2 709 424	2 637 154

Current liabilities
Short-term borrowings from banks	4	319 400	304 900
Payables to brokers		–	5 436
Other short-term liabilities		2 973	3 491
Tax liabilities		114	110
		322 487	313 937
Total liabilities		322 487	313 937

Shareholders' equity
Share capital	5	11 080	11 080
Treasury shares	5	(36 508)	(36 508)
Retained earnings		2 412 365	2 348 645
		2 386 937	2 323 217
Total liabilities and shareholders' equity		2 709 424	2 637 154

Net asset value per share in CHF		43.50	42.35

The notes are an integral part of the condensed consolidated interim financial statements.

The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on July 23, 2024.